212 related articles for article (PubMed ID: 29021516)
21. Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034.
Shah NP; Rousselot P; Schiffer C; Rea D; Cortes JE; Milone J; Mohamed H; Healey D; Kantarjian H; Hochhaus A; Saglio G
Am J Hematol; 2016 Sep; 91(9):869-74. PubMed ID: 27192969
[TBL] [Abstract][Full Text] [Related]
22. Drug-induced chylothorax as a rare pleural complication in dasatinib therapy for chronic myeloid leukaemia.
Ng IK; Ruparel M; Chan EH; Khoo KL
J R Coll Physicians Edinb; 2024 Mar; 54(1):44-47. PubMed ID: 38486345
[TBL] [Abstract][Full Text] [Related]
23. Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity.
Schiffer CA; Cortes JE; Hochhaus A; Saglio G; le Coutre P; Porkka K; Mustjoki S; Mohamed H; Shah NP
Cancer; 2016 May; 122(9):1398-407. PubMed ID: 26998677
[TBL] [Abstract][Full Text] [Related]
24. Chronic myeloid leukemia patients who develop grade I/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusion.
Eskazan AE; Eyice D; Kurt EA; Elverdi T; Yalniz FF; Salihoglu A; Ar MC; Ongoren Aydin S; Baslar Z; Ferhanoglu B; Aydin Y; Tuzuner N; Ozbek U; Soysal T
Leuk Res; 2014 Jul; 38(7):781-7. PubMed ID: 24832371
[TBL] [Abstract][Full Text] [Related]
25. Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients.
Rousselot P; Mollica L; Guilhot J; Guerci A; Nicolini FE; Etienne G; Legros L; Charbonnier A; Coiteux V; Dartigeas C; Escoffre-Barbe M; Roy L; Cony-Makhoul P; Dubruille V; Gardembas M; Huguet F; Réa D; Cayssials E; Guilhot F; Bergeron A; Molimard M; Mahon FX; Cayuela JM; Busque L; Bouchet S
Br J Haematol; 2021 Jul; 194(2):393-402. PubMed ID: 34195988
[TBL] [Abstract][Full Text] [Related]
26. An Analysis of Dasatinib Treatment Patterns in Patients with Chronic Myeloid Leukemia after Experiencing Pleural Effusion during Dasatinib Therapy.
McBride A; Brokars J; Reddy SR; Chang E; Tarbox MH; LeBlanc TW
Acta Haematol; 2023; 146(4):259-266. PubMed ID: 37037194
[TBL] [Abstract][Full Text] [Related]
27. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
Fiskus W; Pranpat M; Balasis M; Bali P; Estrella V; Kumaraswamy S; Rao R; Rocha K; Herger B; Lee F; Richon V; Bhalla K
Clin Cancer Res; 2006 Oct; 12(19):5869-78. PubMed ID: 17020995
[TBL] [Abstract][Full Text] [Related]
28. Dasatinib-induced chylothorax: report of a case and review of the literature.
Chen B; Wu Z; Wang Q; Li W; Cheng D
Invest New Drugs; 2020 Oct; 38(5):1627-1632. PubMed ID: 32248338
[TBL] [Abstract][Full Text] [Related]
29. Pleural Effusion in Dasatinib-Treated Patients With Chronic Myeloid Leukemia in Chronic Phase: Identification and Management.
Cortes JE; Jimenez CA; Mauro MJ; Geyer A; Pinilla-Ibarz J; Smith BD
Clin Lymphoma Myeloma Leuk; 2017 Feb; 17(2):78-82. PubMed ID: 28082112
[TBL] [Abstract][Full Text] [Related]
30. Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia.
Latagliata R; Breccia M; Fava C; Stagno F; Tiribelli M; Luciano L; Gozzini A; Gugliotta G; Annunziata M; Cavazzini F; Ferrero D; Musto P; Capodanno I; Iurlo A; Visani G; Crugnola M; Calistri E; Castagnetti F; Vigneri P; Alimena G
Hematol Oncol; 2013 Jun; 31(2):103-9. PubMed ID: 22815278
[TBL] [Abstract][Full Text] [Related]
31. Differential gene expression analysis of dasatinib-induced colitis in a patient with chronic myeloid leukemia followed for 3 years: a case report.
Oshima N; Mishima Y; Shibagaki K; Kawashima K; Ishimura N; Ikejiri F; Onishi C; Okada T; Inoue M; Moriyama I; Suzumiya J; Kinoshita Y; Ishihara S
BMC Gastroenterol; 2021 Jan; 21(1):19. PubMed ID: 33407162
[TBL] [Abstract][Full Text] [Related]
32. [Chylothorax Related with Dasatinib in the Treatment of Chronic Myeloid Leukemia: Report of 3 Cases].
Yang L; Lu N; Jing Y; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Oct; 24(5):1348-1353. PubMed ID: 27784355
[TBL] [Abstract][Full Text] [Related]
33. [Effect of low-dose dasatinib in an elderly patient with chronic myelogenous leukemia (CML)].
Takagi Y; Aota Y; Gotoh A; Sakurai M
Gan To Kagaku Ryoho; 2010 Nov; 37(11):2213-5. PubMed ID: 21084830
[TBL] [Abstract][Full Text] [Related]
34. [Research advance on molecular genetics of CML blast crisis].
Zhu HQ; Zhang S; Liu XL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Feb; 16(1):217-21. PubMed ID: 18315935
[TBL] [Abstract][Full Text] [Related]
35. Dasatinib: in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Keam SJ
BioDrugs; 2008; 22(1):59-69. PubMed ID: 18215092
[TBL] [Abstract][Full Text] [Related]
36. Clinical Efficacy and Safety of First-Line Dasatinib Therapy and the Relevance of Velocity of BCR-ABL1 Transcript Decline for Achievement of Molecular Responses in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Report from the Juntendo Yamanashi Cooperative Study Group.
Takaku T; Iriyama N; Mitsumori T; Sato E; Gotoh A; Kirito K; Noguchi M; Koike M; Sakamoto J; Oba K; Komatsu N
Oncology; 2018; 94(2):85-91. PubMed ID: 29151104
[TBL] [Abstract][Full Text] [Related]
37. Pleural effusions due to dasatinib.
Brixey AG; Light RW
Curr Opin Pulm Med; 2010 Jul; 16(4):351-6. PubMed ID: 20375898
[TBL] [Abstract][Full Text] [Related]
38. Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.
Shiseki M; Yoshida C; Takezako N; Ohwada A; Kumagai T; Nishiwaki K; Horikoshi A; Fukuda T; Takano H; Kouzai Y; Tanaka J; Morita S; Sakamoto J; Sakamaki H; Inokuchi K
Int J Clin Oncol; 2017 Oct; 22(5):972-979. PubMed ID: 28550414
[TBL] [Abstract][Full Text] [Related]
39. cAMP Signaling Pathway Prevents Dasatinib-Induced Vascular Hyperpermeability.
Aoyama T; Kuriyama H; Sato Y; Imai S; Kashiwagi H; Sugawara M; Takekuma Y
Biol Pharm Bull; 2021; 44(8):1101-1110. PubMed ID: 34334496
[TBL] [Abstract][Full Text] [Related]
40. Dasatinib, large granular lymphocytosis, and pleural effusion: useful or adverse effect?
Paydas S
Crit Rev Oncol Hematol; 2014 Feb; 89(2):242-7. PubMed ID: 24210599
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
